Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
October 24, 2023
Assignees:
BioNTech AG, Astellas Pharma Inc., TRON—Translationale Onkologie an der Universität
Inventors:
Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
October 17, 2023
Assignees:
BioNTech SE, ASTELLAS PHARMA INC.
Inventors:
Ugur Sahin, Christiane Stadler, Leyla Fischer, Arne Jendretzki, Özlem Türeci, Fabrice Le Gall, Maria Kreuzberg
Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The high-purity renal progenitor cells can be used in regenerative medicine for renal diseases, such as renal failure.
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Type:
Grant
Filed:
July 2, 2020
Date of Patent:
August 29, 2023
Assignees:
Astellas Pharma Inc., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄT
Inventors:
Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
August 22, 2023
Assignees:
Astellas Pharma Inc., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH
Inventors:
Ugur Sahin, Ozlem Tureci, Daniel Maurus
Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.
Abstract: Provided is a fast-eluting three-dimensionally molded object, which is formed by fused deposition modeling type three-dimensional molding and quickly elutes an active component. The fast-eluting three-dimensionally molded object is formed by the fused deposition modeling type three-dimensional molding and includes an active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component. The fast-eluting three-dimensionally molded object has an elution rate of the active component of 80% or higher within 85 minutes by a dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.
Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
Abstract: Provided is a pharmaceutical composition that can be administered into the ear without any complicated operation and has a function of allowing a drug to be retained and slowly released in the ear. A pharmaceutical composition for otic administration, comprising one, or two or more drugs and a polymer, wherein when the complex viscosity of the pharmaceutical composition is measured using a rheometer under the conditions of a shear strain of 5% and an angular frequency of 50 rad/sec., while increasing the temperature from 25° C. to 37° C. at a heating rate of 1° C./10 sec., the complex viscosity is less than 1,650 mPa·s at 25° C., and is from 1,650 mPa·s to 100,000 mPa·s at 10 minutes after reaching 37° C.
Type:
Application
Filed:
July 30, 2020
Publication date:
May 25, 2023
Applicant:
Astellas Pharma Inc.
Inventors:
Takatsune YOSHIDA, Mari OSADA, Takaya MATSUDA, Ken SHIMADA, Hiroyuki KOJIMA, Akira NAGAKURA
Abstract: The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
Abstract: A detection unit (88) detects a specific state of a wearer. A signal communication unit (92) wirelessly transmits, to an information processing apparatus, log information indicating a detection result obtained by the detection unit (88) detecting the specific state and a date and time when the specific state is detected. A stimulus application unit (94) applies a stimulus to the wearer when the specific state is detected by the detection unit (88).
Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
Type:
Application
Filed:
December 7, 2022
Publication date:
April 13, 2023
Applicants:
Kyoto University, Astellas Pharma Inc.
Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.
Abstract: Object: To provide an antisense guide RNA for editing a target RNA by ADAR. Solution: An antisense guide RNA for editing a target RNA by ADAR, containing at least one functional region and an antisense region that is complementary to a portion of the target RNA and can form a double strand with the target RNA, in which the at least one functional region is linked to the antisense region, and in which the guide RNA does not substantially contain an ADAR-recruiting base sequence.
Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
January 3, 2023
Assignees:
Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventors:
Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs